These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 9151539)

  • 21. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Proposed rule.
    Fed Regist; 1998 Jun; 63(109):31143-61. PubMed ID: 10180130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical devices; exemption from premarket notification and reserved devices; Class I--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(218):63222-53. PubMed ID: 10187398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The nightmare of FDA clearance/approval to market: perception or reality?
    Tylenda CA
    Technol Health Care; 1996 Sep; 4(3):259-67. PubMed ID: 8931236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical device recalls and the FDA approval process.
    Zuckerman DM; Brown P; Nissen SE
    Arch Intern Med; 2011 Jun; 171(11):1006-11. PubMed ID: 21321283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric circulatory support: an FDA perspective.
    Rinaldi JE; Chen EA; Berman MR
    ASAIO J; 2005; 51(5):533-5. PubMed ID: 16322713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orbital Implants Receiving Food and Drug Administration Premarket Notification.
    Corcoran Ruiz KM; Vaishnav YJ; Desautels J; Schaefer JL; Migliori ME; Yilmaz T
    Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):503-506. PubMed ID: 35699217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New tools of the trade.
    Reamer LA
    Radiology; 1990 Mar; 174(3 Pt 2):923-5. PubMed ID: 2406790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
    Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
    BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical devices; exemptions from premarket notification; class II devices; vascular tunnelers. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Mar; 65(43):11466-7. PubMed ID: 11010650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. International regulatory aspects of clinical periodontal research.
    Cooley WE; Castellion AW
    Ann Periodontol; 1997 Mar; 2(1):18-30. PubMed ID: 9151540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of the FDA and Regulatory Approval of New Devices for Diabetes Care.
    Jazowski SA; Winn AN
    Curr Diab Rep; 2017 Jun; 17(6):40. PubMed ID: 28439847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substantial Equivalence Premarket Review: the Right Approach for Most Medical Devices.
    Shapiro JK
    Food Drug Law J; 2014; 69(3):365-97, i. PubMed ID: 27382855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation and Device Development: Tips for Optimizing Your Experience With the Food and Drug Administration.
    Brooks SS
    Tech Vasc Interv Radiol; 2017 Jun; 20(2):109-115. PubMed ID: 28673647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marketing approval for the lithotripter.
    Nightingale SL; Young FE
    Isr J Med Sci; 1986; 22(7-8):519-23. PubMed ID: 3781809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA regulation of invasive neural recording electrodes: a daunting task for medical innovators.
    Welle C; Krauthamer V
    IEEE Pulse; 2012 Mar; 3(2):37-41. PubMed ID: 22481744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical devices; device tracking; new orders to manufacturers--FDA. Notice.
    Fed Regist; 1998 Mar; 63(42):10638-40. PubMed ID: 10177504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical devices; 30-day notices and 135-day PMA supplement review--FDA. Direct final rule; withdrawal.
    Fed Regist; 1998 Aug; 63(154):42699. PubMed ID: 10182563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2018 Feb; 83(35):7366-88. PubMed ID: 29932613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.